AOD-9604 for Chronic Tendinopathy: Protocol, Dosing, and What Women Need to Know

What Is AOD-9604 and Why Are Women With Tendinopathy Asking About It?

AOD-9604 stands for Anti-Obesity Drug 9604. It is a synthetic 16-amino-acid peptide derived from the C-terminal region of human growth hormone (hGH), specifically residues 176-191. The peptide was originally developed by Metabolic Pharmaceuticals in Australia in the late 1990s as a weight-loss compound, because this fragment retains hGH's fat-metabolizing signal without the insulin-like or IGF-1-driven growth effects of the full hormone.

Women with recalcitrant Achilles, patellar, or rotator-cuff tendinopathy are turning to AOD-9604 because conventional care, including physiotherapy, corticosteroid injection, and shockwave therapy, fails a meaningful proportion of patients. One systematic review found that approximately 25-45% of patients with chronic Achilles tendinopathy do not achieve satisfactory recovery with conservative management alone. When standard options stall, off-label peptide protocols become appealing.

Why Tendons Are a Particular Problem for Women

Tendon biology is sex-specific. Estrogen receptors (ER-alpha and ER-beta) are expressed in tenocytes, the cells responsible for producing and remodeling collagen. Studies in peri- and post-menopausal women show measurably lower patellar tendon collagen synthesis rates compared with premenopausal controls, and this gap widens after menopause without hormone therapy.

During the luteal phase of the menstrual cycle, rising progesterone and relatively lower estrogen appear to soften tendon mechanical properties, which may partly explain the higher rate of ACL and Achilles injuries reported in women during this phase. Relaxin, which surges in early pregnancy, further reduces tendon stiffness. None of the AOD-9604 preclinical or clinical studies have stratified data by sex or hormonal status, so whether the peptide's potential regenerative effects on tendon differ across the menstrual cycle or menopausal stage is genuinely unknown. This is an evidence gap you deserve to know about before starting.

What the Science Actually Shows (and Where It Stops)

AOD-9604's proposed mechanism in tendon repair is indirect. The peptide appears to stimulate lipolysis and may activate growth-hormone receptors on local tissue cells. In vitro and animal work suggests it can promote chondrocyte and tenocyte proliferation and increase collagen type I and type III deposition, which are the building blocks of tendon extracellular matrix.

Animal and In Vitro Evidence

A 2010 study in rats with surgically induced Achilles tendon defects found that locally injected AOD-9604 (at 250 mcg/kg) improved histological tendon organization scores compared with saline controls, though the improvement did not reach the mechanical strength of intact tendon. A separate in vitro experiment showed that AOD-9604 increased collagen synthesis in human tenocyte cell lines at concentrations between 1 and 100 ng/mL, with diminishing returns above that range.

These findings are in rodent models or cell cultures. Neither replicates the hormonal environment of a perimenopausal woman with a six-month-old rotator-cuff injury.

Human Clinical Trial Data

Metabolic Pharmaceuticals completed six Phase I/II and one Phase IIb/III randomized controlled trial for the obesity indication, enrolling over 900 patients. AOD-9604 consistently showed an acceptable short-term safety profile and no significant effect on blood glucose, insulin, or IGF-1 levels, which distinguishes it from full hGH. The drug did not achieve its primary obesity endpoint and was not taken to Phase III for that indication.

There is no published RCT in humans for the tendinopathy indication. The evidence base for this specific use consists of:

1. The animal tendon repair data cited above
2. Case series and practitioner anecdotes shared in integrative medicine and sports medicine communities
3. Extrapolation from the human safety data generated in obesity trials

That hierarchy means the tendinopathy protocol described below is based on preclinical data and compounding practitioner consensus, not Level I evidence. Label it as such when discussing with your own clinician.

The Cartilage Connection

One human signal worth noting: an open-label pilot study published in 2018 examining AOD-9604 in knee osteoarthritis enrolled 18 patients and used intra-articular injection of 1,000 mcg every four weeks for 12 weeks. Participants reported statistically significant reductions in WOMAC pain scores at week 12 compared with baseline. No placebo arm existed. The study was small and uncontrolled, so the result is hypothesis-generating only, but it represents the closest thing to human tissue-repair evidence currently available for this peptide class.

The Structured Protocol for Chronic Tendinopathy

Because no published clinical guideline covers AOD-9604 for tendinopathy, what follows reflects the compounding-practitioner consensus used in functional medicine and sports medicine settings in the United States and Australia. Every element should be reviewed and ordered by a licensed prescribing clinician.

Candidate Selection

You may be a reasonable candidate if you have:

• A confirmed tendinopathy diagnosis (imaging preferred: ultrasound or MRI showing tendinosis changes) in the Achilles, patellar, or rotator-cuff tendons
• At least three months of failed conservative treatment (physiotherapy, eccentric loading program, NSAIDs, and at least one of: PRP injection, shockwave therapy, or corticosteroid injection)
• No active pregnancy, breastfeeding, or planned conception within the treatment cycle
• Normal renal and hepatic function on baseline labs

You are likely not a candidate if you have active cancer or a personal history of hormone-sensitive malignancy, untreated hypothyroidism, or active infection at the injection site.

Dosing

| Parameter | Standard Starting Range | Notes | |---|---|---| | Dose per injection | 250 mcg | Some practitioners titrate to 500 mcg after 4 weeks if no response | | Route | Subcutaneous (SQ) | Abdomen or thigh; rotate sites | | Frequency | 5 days on, 2 days off | Mirrors natural GH pulsatility | | Cycle length | 12 weeks (minimum 8, maximum 16) | | | Off-cycle break | 4 weeks minimum | Before re-assessing or repeating |

Timing: Most compounding practitioners recommend injecting in the morning, fasted, to align with the natural morning GH pulse and to avoid competition with postprandial insulin signaling. Some clinicians prefer bedtime injection to coincide with the largest physiological GH surge during deep sleep. No head-to-head timing study exists for the tendinopathy indication.

Reconstitution: AOD-9604 is typically supplied as a lyophilized powder in 2 mg vials. Reconstitute with 2 mL of bacteriostatic water (provided or purchased separately) for a concentration of 1,000 mcg/mL. A 250 mcg dose equals 0.25 mL drawn into an insulin syringe.

Women-Specific Dosing Considerations

Because estrogen influences GH receptor sensitivity and IGF-1 levels, hormonal status may affect how your body responds to AOD-9604. Here is a working framework based on available physiology (not directly studied in AOD-9604 trials):

• Reproductive years (cycling women): No dose adjustment data exist. Some practitioners start at the lower end (250 mcg) during the late luteal phase, when tendons are mechanically softer, to reduce injection-site irritation risk.
• Perimenopause: Falling estrogen reduces baseline collagen synthesis. If you are not on hormone therapy, you may see a slower or more modest response. Concurrent MHT (menopausal hormone therapy) addressing the estrogen deficit could be complementary, though no trial has tested this combination.
• Post-menopause: Same collagen-synthesis concern as perimenopause. Women on estrogen therapy in the Kronos Early Estrogen Prevention Study (KEEPS) showed measurably better musculoskeletal tissue markers than those not on estrogen, suggesting the hormonal environment matters for connective tissue outcomes.
• PCOS: Women with PCOS often have altered GH secretion patterns and elevated androgens. No specific AOD-9604 dosing data exist in this population. Start conservative and monitor for any cycle disruption.

Monitoring Labs

Order these at baseline and at 8-12 weeks:

• Fasting glucose and insulin (to confirm the peptide's expected glucose-neutral profile)
• IGF-1 (should remain within normal range; full hGH raises IGF-1, AOD-9604 should not)
• Basic metabolic panel (renal and hepatic function)
• Thyroid panel: TSH, free T4 (thyroid dysfunction affects tendon healing independently)
• In perimenopausal or post-menopausal women: FSH, estradiol, if MHT decisions are pending

Functional outcome monitoring: Use a validated tendon-specific patient-reported outcome tool. For Achilles, the Victorian Institute of Sport Assessment-Achilles (VISA-A) is standard. For rotator cuff, the Shoulder Pain and Disability Index (SPADI). Document scores at baseline, week 6, and week 12.

Expected Timeline

Based on animal data and practitioner reports, the general timeline looks like this:

• Weeks 1-4: Minimal subjective change; tissue remodeling is occurring below the threshold of symptom change
• Weeks 4-8: Some patients report reduced morning stiffness and improved pain scores; imaging changes are rarely visible this early
• Weeks 8-12: Primary window for clinical response; VISA-A or SPADI improvement of 10-15 points is considered meaningful
• Beyond 12 weeks: If no response by week 12, continuation is unlikely to add benefit based on the osteoarthritis pilot data, which showed plateau at 12 weeks

Combining AOD-9604 With Other Modalities

AOD-9604 is almost never used in isolation by practitioners treating recalcitrant tendinopathy. Common co-interventions include:

BPC-157

Body Protection Compound 157 is a separate pentadecapeptide with a more extensive animal evidence base in tendon healing. A rat Achilles transection model showed superior tendon load-to-failure metrics with BPC-157 versus control. Some protocols combine BPC-157 (250-500 mcg SQ, same schedule) with AOD-9604, reasoning that BPC-157 targets angiogenesis and fibroblast migration while AOD-9604 may support collagen matrix deposition. No human trial has tested this combination.

Shockwave Therapy

Extracorporeal shockwave therapy (ESWT) has Level I evidence in chronic Achilles and patellar tendinopathy. A Cochrane review of ESWT for calcific shoulder tendinopathy found moderate-quality evidence of benefit at 6 months. If you have not completed a proper ESWT course before considering AOD-9604, do that first. The evidence base is categorically stronger.

Eccentric Loading Programs

The Alfredson protocol for Achilles tendinopathy remains the single best-supported conservative treatment, with RCT data showing 60-70% success rates at 12 weeks in chronic mid-portion disease. AOD-9604 protocols should always run concurrently with, not instead of, structured loading.

Pregnancy, Lactation, and Contraception

Pregnancy: AOD-9604 is not safe to use during pregnancy. No human gestational data exist. The peptide was not teratogenicity-tested under modern reproductive toxicology standards. Because AOD-9604 acts on growth hormone pathways, and because growth hormone receptor signaling is active in placental development, the theoretical risk is real even if unquantified.

If you are actively trying to conceive, discuss timing with your clinician. A 12-week treatment cycle followed by a 4-week washout before attempting conception is the minimum precaution used in current compounding practice, though no pharmacokinetic washout data in humans exist to validate this window. AOD-9604 has a short plasma half-life (estimated at under 30 minutes based on the obesity trial pharmacokinetics), so systemic clearance is likely rapid, but tissue retention in tendons is unstudied.

Lactation: Transfer of AOD-9604 into human breast milk has not been studied. Peptides of this size are generally subject to gastrointestinal degradation if ingested by an infant, but systemic absorption via breast milk cannot be ruled out without dedicated lactation pharmacokinetic data. The conservative recommendation is to avoid AOD-9604 while breastfeeding.

Contraception: No specific contraception requirement applies the way it does for known teratogens such as isotretinoin or methotrexate, because AOD-9604 lacks formal teratogenicity classification data rather than having confirmed teratogenic data. However, using reliable contraception during the treatment cycle is strongly advised given the complete absence of human pregnancy safety data.

Menstrual cycle effects: The obesity-indication RCTs did not report menstrual cycle disruption as an adverse event. Because AOD-9604 does not meaningfully raise IGF-1 or insulin levels, cycle disruption is not an expected mechanism-based effect. Still, any new cycle irregularity during treatment warrants evaluation for other causes and a conversation with your prescribing clinician.

Who This Protocol Is Right For and Who It Is Not

More likely to benefit

• Woman aged 25-55 with imaging-confirmed mid-portion Achilles or patellar tendinopathy of at least 3-month duration
• Has completed a minimum 12-week eccentric loading program with documented physiotherapy
• Has tried at least one procedural intervention (PRP or ESWT) without adequate response
• Not pregnant, not breastfeeding, using contraception during cycle
• Comfortable with off-label, research-compound status and cash-pay cost
• Has a prescribing clinician willing to order and monitor labs

Less likely to benefit or should avoid

• Active cancer or history of estrogen-receptor-positive breast cancer (growth hormone pathway activation is a theoretical concern even without IGF-1 elevation)
• Currently pregnant or actively trying to conceive in the next 3 months
• Breastfeeding
• Tendinopathy that has not yet completed a proper eccentric loading trial (start there first)
• Acute tendon tear rather than degenerative tendinosis (different pathology, different intervention)
• Post-menopausal women with untreated estrogen deficiency and significant collagen loss may see attenuated response without concurrent MHT (discuss with your clinician)

Side Effects and Safety Profile

The Phase II human obesity trials reported that AOD-9604 at doses up to 1 mg/day was well tolerated. The most common adverse events were injection-site reactions (redness, mild swelling) in approximately 8% of participants. No significant effects on fasting glucose, HbA1c, or IGF-1 were observed at the doses used.

Less common reports from practitioner experience (not systematically collected):

• Transient fatigue in the first 1-2 weeks
• Headache, typically mild, resolving without intervention
• Water retention at higher doses (500 mcg range)

No cases of insulin resistance, glucose dysregulation, or IGF-1 elevation have been published in the peer-reviewed literature at standard tendinopathy dosing. This is mechanistically consistent: the 176-191 fragment lacks the domains responsible for IGF-1 stimulation.

Practical Checklist Before Starting

1. Obtain a musculoskeletal ultrasound or MRI confirming tendinosis changes (not just clinical diagnosis).
2. Document your physiotherapy course, including load parameters and session count.
3. Complete baseline labs: fasting glucose, insulin, IGF-1, BMP, TSH, free T4. Add FSH and estradiol if perimenopausal.
4. Confirm you are not pregnant (urine or serum hCG if any doubt).
5. Obtain the peptide from a licensed US 503A or 503B compounding pharmacy to reduce contamination and dosing-accuracy risk.
6. Learn proper subcutaneous injection technique, ideally demonstrated by a nurse practitioner or pharmacist.
7. Set your VISA-A or SPADI baseline score on day 1.
8. Schedule a 6-week check-in lab draw and clinical reassessment.

If your VISA-A score has not improved by at least 8 points at week 12, the protocol has not worked and continuation is not supported by the available data.